Login / Signup

Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8 + T-cells.

Caroline PassaesDelphine DesjardinsAnaïs ChapelValérie MonceauxJulien LemaitreAdeline MélardFederico Perdomo-CelisCyril PlanchaisMaël GourvèsNastasia DimantAnnie DavidNathalie BosquetAurélie Barrail-TranHélène GougetCéline GuillaumeFrancis RelouzatOlivier LambotteJeremie GuedjMichaela Müller-TrutwinHugo MouquetChristine RouziouxVeronique Avettand-FenoelRoger Le GrandAsier Sáez-Cirión
Published in: Nature communications (2024)
HIV remission can be achieved in some people, called post-treatment HIV controllers, after antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was suggested to favor post-treatment control, but the circumstances and mechanisms leading to this outcome remain unclear. Here we evaluate the impact of early (week 4) vs. late (week 24 post-infection) treatment initiation in SIVmac 251 -infected male cynomolgus macaques receiving 2 years of therapy before analytical treatment interruption. We show that early treatment strongly promotes post-treatment control, which is not related to a lower frequency of infected cells at treatment interruption. Rather, early treatment favors the development of long-term memory CD8 + T cells with enhanced proliferative and SIV suppressive capacity that are able to mediate a robust secondary-like response upon viral rebound. Our model allows us to formally demonstrate a link between treatment initiation during primary infection and the promotion of post-treatment control and provides results that may guide the development of new immunotherapies for HIV remission.
Keyphrases
  • antiretroviral therapy
  • hiv infected
  • stem cells
  • human immunodeficiency virus
  • oxidative stress
  • clinical trial
  • mesenchymal stem cells
  • combination therapy
  • south africa
  • double blind